BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stichweh DS, Punaro M, Pascual V. Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. Pediatr Dermatol. 2005;22:262-265. [PMID: 15916580 DOI: 10.1111/j.1525-1470.2005.22320.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Rigante D, Capoluongo E. The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clin Chem Lab Med 2011;49:783-91. [PMID: 21275813 DOI: 10.1515/CCLM.2011.127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
2 Saternus R, Schwingel J, Müller CSL, Vogt T, Reichrath J. Ancient friends, revisited: Systematic review and case report of pyoderma gangrenosum-associated autoinflammatory syndromes. J Transl Autoimmun 2020;3:100071. [PMID: 33305249 DOI: 10.1016/j.jtauto.2020.100071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mistry P, Carmona-Rivera C, Ombrello AK, Hoffmann P, Seto NL, Jones A, Stone DL, Naz F, Carlucci P, Dell'Orso S, Gutierrez-Cruz G, Sun HW, Kastner DL, Aksentijevich I, Kaplan MJ. Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome. Ann Rheum Dis 2018;77:1825-33. [PMID: 30131320 DOI: 10.1136/annrheumdis-2018-213746] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
4 Hofmann SR, Morbach H, Schwarz T, Rösen-Wolff A, Girschick HJ, Hedrich CM. Attenuated TLR4/MAPK signaling in monocytes from patients with CRMO results in impaired IL-10 expression. Clin Immunol 2012;145:69-76. [PMID: 22940633 DOI: 10.1016/j.clim.2012.07.012] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
5 Díaz-ley B, Guhl G, Fernández-herrera J. Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Primera parte: infliximab y adalimumab. Actas Dermo-Sifiliográficas 2007;98:657-78. [DOI: 10.1016/s0001-7310(07)70159-x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
6 Aróstegui JI, Yagüe J. [Hereditary systemic autoinflammatory diseases. Part II: cryopyrin-associated periodic syndromes, pediatric systemic granulomatosis and PAPA syndrome]. Med Clin (Barc) 2008;130:429-38. [PMID: 18394369 DOI: 10.1157/13117854] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
7 Garcovich S, De Simone C, Berti E, Marzano AV. Drug management of neutrophilic dermatoses. Expert Rev Clin Pharmacol 2017;10:1119-28. [PMID: 28715916 DOI: 10.1080/17512433.2017.1356719] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
8 Nguyen TV, Cowen EW, Leslie KS. Autoinflammation: From monogenic syndromes to common skin diseases. J Am Acad Dermatol 2013;68:834-53. [PMID: 23453357 DOI: 10.1016/j.jaad.2012.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
9 Smith EJ, Allantaz F, Bennett L, Zhang D, Gao X, Wood G, Kastner DL, Punaro M, Aksentijevich I, Pascual V, Wise CA. Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Curr Genomics 2010;11:519-27. [PMID: 21532836 DOI: 10.2174/138920210793175921] [Cited by in Crossref: 120] [Cited by in F6Publishing: 74] [Article Influence: 12.0] [Reference Citation Analysis]
10 Martinez-Rios C, Jariwala MP, Highmore K, Duffy KW, Spiegel L, Laxer RM, Stimec J. Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature. Pediatr Radiol. 2019;49:23-36. [PMID: 30225645 DOI: 10.1007/s00247-018-4246-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
11 Miller J, Yentzer BA, Clark A, Jorizzo JL, Feldman SR. Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol. 2010;62:646-654. [PMID: 20227580 DOI: 10.1016/j.jaad.2009.05.030] [Cited by in Crossref: 134] [Cited by in F6Publishing: 86] [Article Influence: 12.2] [Reference Citation Analysis]
12 Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U. Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol 2013;9:1161-70. [PMID: 23902247 DOI: 10.2217/fon.13.62] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
13 Verbsky JW. Monogenic causes of inflammatory disease in rheumatology. Curr Opin Rheumatol 2012;24:506-14. [PMID: 22832824 DOI: 10.1097/BOR.0b013e32835689b9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, Keller M, Kobrynski LJ, Komarow HD, Mazer B. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136:1186-1205.e1-78. [PMID: 26371839 DOI: 10.1016/j.jaci.2015.04.049] [Cited by in Crossref: 292] [Cited by in F6Publishing: 211] [Article Influence: 48.7] [Reference Citation Analysis]
15 Berk DR, Bayliss SJ. Neutrophilic dermatoses in children. Pediatr Dermatol 2008;25:509-19. [PMID: 18950391 DOI: 10.1111/j.1525-1470.2008.00765.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
16 Bellodi-schmidt F, Shah KN. Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology. Pediatr Dermatol 2016;33:18-27. [DOI: 10.1111/pde.12707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Martorana D, Bonatti F, Mozzoni P, Vaglio A, Percesepe A. Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations. Front Immunol 2017;8:344. [PMID: 28421071 DOI: 10.3389/fimmu.2017.00344] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
18 Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med 2014;65:223-44. [PMID: 24422572 DOI: 10.1146/annurev-med-061512-150641] [Cited by in Crossref: 187] [Cited by in F6Publishing: 140] [Article Influence: 26.7] [Reference Citation Analysis]
19 Löffler W, Lohse P, Weihmayr T, Widenmayer W. Pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts. Infection 2017;45:395-402. [PMID: 28251506 DOI: 10.1007/s15010-017-0996-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
20 Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F, Brizi MG, Guerrini S, Patti M, Punzi L, Galeazzi M, Cantarini L. Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm 2013;2013:939847. [PMID: 23970817 DOI: 10.1155/2013/939847] [Cited by in Crossref: 60] [Cited by in F6Publishing: 46] [Article Influence: 7.5] [Reference Citation Analysis]
21 Verbsky JW. When to Suspect Autoinflammatory/Recurrent Fever Syndromes. Pediatric Clinics of North America 2017;64:111-25. [DOI: 10.1016/j.pcl.2016.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 Grosse J, Chitu V, Marquardt A, Hanke P, Schmittwolf C, Zeitlmann L, Schropp P, Barth B, Yu P, Paffenholz R, Stumm G, Nehls M, Stanley ER. Mutation of mouse Mayp/Pstpip2 causes a macrophage autoinflammatory disease. Blood 2006;107:3350-8. [PMID: 16397132 DOI: 10.1182/blood-2005-09-3556] [Cited by in Crossref: 112] [Cited by in F6Publishing: 92] [Article Influence: 7.5] [Reference Citation Analysis]
23 Samuels J, Ozen S. Familial Mediterranean fever and the other autoinflammatory syndromes: evaluation of the patient with recurrent fever: . Current Opinion in Rheumatology 2006;18:108-17. [DOI: 10.1097/01.bor.0000198006.65697.5b] [Cited by in Crossref: 89] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
24 Cox N, Jorizzo JL, Bourke JF, Savage COS. Vasculitis, Neutrophilic Dermatoses and Related Disorders. In: Burns T, Breathnach S, Cox N, Griffiths C, editors. Rook's Textbook of Dermatology. Oxford: Wiley-Blackwell; 2010. pp. 1-95. [DOI: 10.1002/9781444317633.ch50] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Rigante D. The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 2012;11:348-56. [PMID: 22024500 DOI: 10.1016/j.autrev.2011.10.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
26 Reguia?? Z, Grange F. The Role of Anti-Tumor Necrosis Factor-?? Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease: . American Journal of Clinical Dermatology 2007;8:67-77. [DOI: 10.2165/00128071-200708020-00002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
27 Jackson JM, Callen JP. Pyoderma gangrenosum: an expert commentary. Expert Review of Dermatology 2014;1:391-400. [DOI: 10.1586/17469872.1.3.391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
28 Holzinger D, Roth J. Alarming consequences - autoinflammatory disease spectrum due to mutations in proline-serine-threonine phosphatase-interacting protein 1. Curr Opin Rheumatol 2016;28:550-9. [PMID: 27464597 DOI: 10.1097/BOR.0000000000000314] [Cited by in Crossref: 40] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
29 Leiding JW, Forbes LR. Mechanism-Based Precision Therapy for the Treatment of Primary Immunodeficiency and Primary Immunodysregulatory Diseases. The Journal of Allergy and Clinical Immunology: In Practice 2019;7:761-73. [DOI: 10.1016/j.jaip.2018.12.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
30 Defilippis E, Feldman S, Huang W. The genetics of pyoderma gangrenosum and implications for treatment: a systematic review. Br J Dermatol 2015;172:1487-97. [DOI: 10.1111/bjd.13493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 32] [Article Influence: 9.5] [Reference Citation Analysis]
31 McKenzie F, Cash D, Gupta A, Cummings LW, Ortega-Loayza AG. Biologic and small-molecule medications in the management of pyoderma gangrenosum. J Dermatolog Treat 2019;30:264-76. [PMID: 30051737 DOI: 10.1080/09546634.2018.1506083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
32 Tofteland ND, Shaver TS. Clinical efficacy of etanercept for treatment of PAPA syndrome. J Clin Rheumatol 2010;16:244-5. [PMID: 20661073 DOI: 10.1097/RHU.0b013e3181e969b9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 15] [Article Influence: 4.4] [Reference Citation Analysis]
33 Demidowich AP, Freeman AF, Kuhns DB, Aksentijevich I, Gallin JI, Turner ML, Kastner DL, Holland SM. Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum. 2012;64:2022-2027. [PMID: 22161697 DOI: 10.1002/art.34332] [Cited by in Crossref: 123] [Cited by in F6Publishing: 83] [Article Influence: 12.3] [Reference Citation Analysis]
34 Hoffman MD. Inflammatory ulcers. Clinics in Dermatology 2007;25:131-8. [DOI: 10.1016/j.clindermatol.2006.09.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
35 Lu L, Tang X, Luo G, Tang M, Liu Y, Yu X. Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome in a Chinese family: A case report and review of literature. WJCC 2021;9:6393-402. [DOI: 10.12998/wjcc.v9.i22.6393] [Reference Citation Analysis]
36 Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409-415. [PMID: 21745697 DOI: 10.1016/j.jaad.2010.12.025] [Cited by in Crossref: 202] [Cited by in F6Publishing: 135] [Article Influence: 20.2] [Reference Citation Analysis]
37 Bodar EJ, Drenth JP, van der Meer JW, Simon A. Dysregulation of innate immunity: hereditary periodic fever syndromes. Br J Haematol 2009;144:279-302. [PMID: 19120372 DOI: 10.1111/j.1365-2141.2008.07036.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
38 Cugno M, Borghi A, Marzano AV. PAPA, PASH and PAPASH Syndromes: Pathophysiology, Presentation and Treatment. Am J Clin Dermatol 2017;18:555-62. [DOI: 10.1007/s40257-017-0265-1] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 15.3] [Reference Citation Analysis]
39 Scully C, Hodgson T, Lachmann H. Auto-inflammatory syndromes and oral health. Oral Dis 2008;14:690-9. [PMID: 19193198 DOI: 10.1111/j.1601-0825.2008.01484.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
40 Levin J, Werth VP. Skin disorders with arthritis. Best Pract Res Clin Rheumatol 2006;20:809-26. [PMID: 16979539 DOI: 10.1016/j.berh.2006.05.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
41 Yamamoto T. Pyoderma gangrenosum: An important dermatologic condition occasionally associated with rheumatic diseases. WJR 2015;5:101. [DOI: 10.5499/wjr.v5.i2.101] [Cited by in CrossRef: 3] [Article Influence: 0.5] [Reference Citation Analysis]
42 Pithukpakorn M, Aksentijevich I, Toro JR. Autoinflammatory Diseases: Clinical and Dermatologic Features, Genetics, Pathogenesis and Therapy. Advances in Dermatology 2006;22:67-90. [DOI: 10.1016/j.yadr.2006.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
43 Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. 2017;18:355-372. [PMID: 28224502 DOI: 10.1007/s40257-017-0251-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 54] [Article Influence: 32.7] [Reference Citation Analysis]
44 Posso-de Los Rios CJ, Pope E. New insights into pustular dermatoses in pediatric patients. Journal of the American Academy of Dermatology 2014;70:767-73. [DOI: 10.1016/j.jaad.2013.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
45 Omenetti A, Carta S, Caorsi R, Finetti M, Marotto D, Lattanzi B, Jorini M, Delfino L, Penco F, Picco P, Buoncompagni A, Martini A, Rubartelli A, Gattorno M. Disease activity accounts for long-term efficacy of IL-1 blockers in pyogenic sterile arthritis pyoderma gangrenosum and severe acne syndrome. Rheumatology (Oxford). 2016;55:1325-1335. [PMID: 26989109 DOI: 10.1093/rheumatology/kew031] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
46 Cugno M, Gualtierotti R, Meroni PL, Marzano AV. Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review. Clinic Rev Allerg Immunol 2018;54:269-81. [DOI: 10.1007/s12016-017-8629-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
47 Rigante D, Lopalco G, Vitale A, Lucherini OM, Caso F, De Clemente C, Molinaro F, Messina M, Costa L, Atteno M, Laghi-Pasini F, Lapadula G, Galeazzi M, Iannone F, Cantarini L. Untangling the web of systemic autoinflammatory diseases. Mediators Inflamm 2014;2014:948154. [PMID: 25132737 DOI: 10.1155/2014/948154] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
48 Marzano AV, Borghi A, Meroni PL, Cugno M. Pyoderma gangrenosum and its syndromic forms: evidence for a link with autoinflammation. Br J Dermatol. 2016;175:882-891. [PMID: 27106250 DOI: 10.1111/bjd.14691] [Cited by in Crossref: 84] [Cited by in F6Publishing: 48] [Article Influence: 16.8] [Reference Citation Analysis]
49 Touitou I, Koné-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008;22:811-29. [PMID: 19028365 DOI: 10.1016/j.berh.2008.08.009] [Cited by in Crossref: 87] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
50 Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin 2013;31:405-25. [PMID: 23827244 DOI: 10.1016/j.det.2013.04.001] [Cited by in Crossref: 55] [Cited by in F6Publishing: 31] [Article Influence: 6.9] [Reference Citation Analysis]
51 Moll M, Kuemmerle-deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology 2013;147:242-75. [DOI: 10.1016/j.clim.2013.04.008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 7.0] [Reference Citation Analysis]
52 Ohashi T, Miura T, Yamamoto T. Auricular pyoderma gangrenosum with penetration in a patient with rheumatoid arthritis. Int J Rheum Dis. 2014;Jun 10; Epub ahead of print. [PMID: 24916772 DOI: 10.1111/1756-185x.12411] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
53 Adışen E, Öztaş M, Gürer MA. Treatment of Idiopathic Pyoderma Gangrenosum with Infliximab: Induction Dosing Regimen or On-Demand Therapy? Dermatology 2008;216:163-5. [DOI: 10.1159/000111515] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
54 Wang KC, Zane LT. Recent Advances in Acne Vulgaris Research: Insights and Clinical Implications. Advances in Dermatology 2008;24:197-209. [DOI: 10.1016/j.yadr.2008.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
55 Renn C, Helmer A, Megahed M. Pyogene Arthritis, Pyoderma gangraenosum und Akne-Syndrom (PAPA-Syndrom). Hautarzt 2007;58:383-4. [DOI: 10.1007/s00105-007-1331-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lolis MS, Bowe WP, Shalita AR. Acne and Systemic Disease. Medical Clinics of North America 2009;93:1161-81. [DOI: 10.1016/j.mcna.2009.08.008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
57 Chen W, Obermayer-pietsch B, Hong J, Melnik B, Yamasaki O, Dessinioti C, Ju Q, Liakou A, Al-khuzaei S, Katsambas A, Ring J, Zouboulis C. Acne-associated syndromes: models for better understanding of acne pathogenesis: Acne-associated syndromes. Journal of the European Academy of Dermatology and Venereology 2011;25:637-46. [DOI: 10.1111/j.1468-3083.2010.03937.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
58 Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199-1201. [PMID: 19673875 DOI: 10.1111/j.1365-2133.2009.09404.x] [Cited by in Crossref: 151] [Cited by in F6Publishing: 110] [Article Influence: 12.6] [Reference Citation Analysis]
59 Marzano AV, Borghi A, Wallach D, Cugno M. A Comprehensive Review of Neutrophilic Diseases. Clinic Rev Allerg Immunol 2018;54:114-30. [DOI: 10.1007/s12016-017-8621-8] [Cited by in Crossref: 63] [Cited by in F6Publishing: 37] [Article Influence: 15.8] [Reference Citation Analysis]
60 Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am. 2007;33:787-802, vi. [PMID: 18037117 DOI: 10.1016/j.rdc.2007.07.016] [Cited by in Crossref: 115] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
61 Barbato MT, Bakos L, Masiero NCMS, Bolson P. Perfil clinicopatológico dos pacientes com pioderma gangrenoso do Hospital das Clínicas de Porto Alegre (RS) - Brasil (2000-2006). An Bras Dermatol 2008;83:431-6. [DOI: 10.1590/s0365-05962008000500006] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
62 Henderson C, Goldbach-Mansky R. Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Curr Opin Rheumatol 2010;22:567-78. [PMID: 20671522 DOI: 10.1097/BOR.0b013e32833ceff4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 23] [Article Influence: 0.5] [Reference Citation Analysis]
63 Staub J, Pfannschmidt N, Strohal R, Braun-Falco M, Lohse P, Goerdt S, Leverkus M. Successful treatment of PASH syndrome with infliximab, cyclosporine and dapsone. J Eur Acad Dermatol Venereol 2015;29:2243-7. [PMID: 25352307 DOI: 10.1111/jdv.12765] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 5.9] [Reference Citation Analysis]
64 Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73:691-698. [PMID: 26253362 DOI: 10.1016/j.jaad.2015.06.021] [Cited by in Crossref: 116] [Cited by in F6Publishing: 67] [Article Influence: 19.3] [Reference Citation Analysis]
65 Tegtmeyer K, Atassi G, Zhao J, Maloney NJ, Lio PA. Off-Label studies on anakinra in dermatology: a review. J Dermatolog Treat 2020;:1-14. [PMID: 32279586 DOI: 10.1080/09546634.2020.1755417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]